Health
Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal
After shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences. Setara is getting a fresh $90 million…
- Published
- (2 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 34-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Sanofi has no plans for a 'major' overhaul as Dupixent's patent cliff loomsIt’s been six months since Belén Garijo took over as the CEO for Sanofi, and the French drugmaker said Friday it is not planning “major” changes to its business or R&;D pipeline as the early ...After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire→ Former Be Biopharma chief Joanne Smith-Farrell has landed at Orbis Medicines, an Eli Lilly- and Novo-backed startup that's developing oral macrocycles. Smith-Farrell replaces co-founder Morten Graugaard as CEO of Orbis ...Post-Hoc Live: Is biotech’s future full of zero- and one- employee startups?🎙️Watch today at 10:30 am ET 🦾 After Endpoints News’ AI event in New York this month, I had dinner with some of our guests. Over a few ...AstraZeneca follows GSK with $1.5B annual savings pushBattered by late-stage trial failures and determined to meet its ambitious $80 billion-by-2030 revenue goal, AstraZeneca is cutting costs. The company said Friday that it was shifting resources with ...Aspen Neuroscience lands $141M IPO, while Bambusa secures $169MA Parkinson's cell therapy biotech and an I&;I startup from former BioNTech leaders will join the public markets on Friday, extending a sizzling IPO streak for drug developers. Aspen Neuroscience will collect ...For Lilly, cash-pay is key in the US and, increasingly, abroadEli Lilly already knows Americans are willing to shell out hundreds of dollars a month for obesity drugs. Its bet on selling directly to patients helped it build a substantialThis page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
